(P135) Quantitative Assessment of Target Delineation Variability for Thymic Cancers: Agreement Evaluation of a Prospective Segmentation Challenge

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Expert agreement for definitive-case volumes was exceptionally high, although significantly lower agreement was noted postoperatively. Technique and dose prescription between experts were substantively consistent, and these preliminary results will be utilized to create an expert-consensus contouring atlas to aid the nonexpert radiation oncologist in the planning of these challenging, rare tumors.

Emma B. Holliday, MD, Clifton D. Fuller, MD, PhD, Jayashree Kalpathy-Cramer, PhD, Daniel Gomez, MD, Andreas Rimner, MD, PhD, Ying Li, MD, PhD, Suresh Senan, MD, PhD, Lynn D. Wilson, MD, MPH, Jehee Choi, MD, Ritsuko Komaki, MD, Charles R. Thomas, MD; UT MD Anderson Cancer Center; Martinos Center for Biomedical Imaging Center, Massachusetts General Hospital, Harvard Medical School; Memorial Sloan-Kettering Cancer Center; UT Health Science Center, San Antonio; VU Medical Center; Yale University; Loyola University; Oregon Health and Science University Knight Cancer Institute

PURPOSE: We sought to quantitatively determine the relative interobserver variability of expert target volume delineation as part of a larger standardization effort to develop an expert-consensus contouring atlas to complement radiotherapy recommendations for thymic cancers.

METHODS: A pilot dataset was created, consisting of a standardized case presentation with anonymized pre- and postoperative DICOM computed tomography (CT) image sets from a single patient with Masaoka-Koga stage III thymoma. Participating expert thoracic radiation oncologists delineated tumor targets on the pre- and postoperative scans as they would for a definitive and adjuvant case, respectively. Respondents then completed a survey detailing the dose prescription and planning target volume (PTV) margins that they would recommend in definitive and postoperative (ie, R1 vs R2) scenarios. Interobserver variability was analyzed quantitatively with Warfield’s simultaneous truth and performance-level estimation (STAPLE) algorithm and the Dice similarity coefficient (DSC).

RESULTS: Seven users completed the contouring tasks for definitive and adjuvant cases; of these users, five completed online surveys. Segmentation performance was assessed, with high mean ± SD STAPLE-estimated segmentation sensitivity for definitive-case gross tumor volume (GTV) and clinical target volume (CTV) at 0.77 and 0.80, respectively, and postoperative CTV sensitivity of 0.55; all volumes had a specificity of ≥ 0.99. Interobserver agreement was markedly higher for the definitive-case target volumes, with mean ± SD DSC of 0.88 ± 0.03 and 0.89 ± 0.04 for GTV and CTV, respectively, compared with postoperative CTV DSC of 0.69 ±0 .06 (Kruskal-Wallis: P < .01).

CONCLUSION: Expert agreement for definitive-case volumes was exceptionally high, although significantly lower agreement was noted postoperatively. Technique and dose prescription between experts were substantively consistent, and these preliminary results will be utilized to create an expert-consensus contouring atlas to aid the nonexpert radiation oncologist in the planning of these challenging, rare tumors.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content